GLP1R and Hypoglycemia: It also showed that the dose escalation could not rise the occurrence rates of total, severe, gastrointestinal adverse events and hypoglycemia (<i>P>0.05</i>); Compared with 5mg, tirzepatide 10mg and 15mg were associated with more frequent nausea (<i>P<0.001</i>), discontinuation (<i>P<0.05</i>) and injection-site reaction (<i>P<0.01</i>); The rates of vomiting and diarrhea were dose-dependence at the range of 5-15mg.<h4>Conclusion</h4>The safety profile of tirzepatide is generally acceptable, similar to GLP-1 RAs.